BioTuesdays

Tag - ALS

Flex Pharma focused on 3 clinical readouts in 2018

Flex Pharma (NASDAQ:FLKS) expects to report clinical readouts in 2018 from three Phase 2 studies of its anti-cramping drug candidate, FLX-787, in amyotrophic lateral sclerosis (ALS), Charcot-Marie-Tooth disease (CMT)...

Subscribe

Sign up to our weekly BioTuesdays newsletter.